当前位置: 首页 >> 检索结果
382. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
作者: W J Sandborn.;S B Hanauer.;P Rutgeerts.;R N Fedorak.;M Lukas.;D G MacIntosh.;R Panaccione.;D Wolf.;J D Kent.;B Bittle.;J Li.;P F Pollack.
来源: Gut. 2007年56卷9期1232-9页
Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease in the CLASSIC I trial.
383. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones.
作者: Michele Pier Luca Guarino.;Ping Cong.;Michele Cicala.;Rossana Alloni.;Simone Carotti.;Jose Behar.
来源: Gut. 2007年56卷6期815-20页
To examine the mechanisms of action of ursodeoxycholic acid (UDCA) on gallbladder (GB) muscle cells in patients with symptomatic cholesterol gallstones (GSs) as it reduces the incidence of acute cholecystitis.
384. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
作者: F Bonino.;P Marcellin.;G K K Lau.;S Hadziyannis.;R Jin.;T Piratvisuth.;G Germanidis.;C Yurdaydin.;M Diago.;S Gurel.;M-Y Lai.;M R Brunetto.;P Farci.;M Popescu.;P McCloud.; .
来源: Gut. 2007年56卷5期699-705页
In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of pre-treatment factors on post-treatment responses was investigated.
385. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
作者: Jan M H Van den Brande.;Tamara C Koehler.;Zuzana Zelinkova.;Roelof J Bennink.;Anje A te Velde.;Fibo J W ten Cate.;Sander J H van Deventer.;Maikel P Peppelenbosch.;Daniël W Hommes.
来源: Gut. 2007年56卷4期509-17页
The human anti-tumour necrosis factor (TNF) antibody infliximab binds to the membrane TNF and subsequently induces apoptosis of activated lamina propria T lymphocytes in patients with Crohn's disease in vitro.
386. A pilot study in patients with established advanced liver fibrosis using pirfenidone.
作者: J Armendáriz-Borunda.;M C Islas-Carbajal.;E Meza-García.;A R Rincón.;S Lucano.;A S Sandoval.;A Salazar.;J Berumen.;A Alvarez.;A Covarrubias.;G Aréchiga.;L García.
来源: Gut. 2006年55卷11期1663-5页 387. Treatment for painful calcified chronic pancreatitis: extracorporeal shock wave lithotripsy versus endoscopic treatment: a randomised controlled trial.
作者: Jean-Marc Dumonceau.;Guido Costamagna.;Andrea Tringali.;Kouroche Vahedi.;Myriam Delhaye.;Axel Hittelet.;Gianluca Spera.;Emiliano Giostra.;Massimiliano Mutignani.;Viviane De Maertelaer.;Jacques Devière.
来源: Gut. 2007年56卷4期545-52页
In chronic pancreatitis, obstruction of the main pancreatic duct (MPD) may contribute to the pathogenesis of pain. Pilot studies suggest that extracorporeal shock wave lithotripsy (ESWL) alone relieves pain in calcified chronic pancreatitis.
388. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.
作者: Rocco Maurizio Zagari.;Gabriele Bianchi-Porro.;Roberto Fiocca.;Giovanni Gasbarrini.;Enrico Roda.;Franco Bazzoli.
来源: Gut. 2007年56卷4期475-9页
Triple therapy is recommended for Helicobacter pylori eradication, yet consensus on the duration of treatment is lacking.
389. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
作者: Ming-Lung Yu.;Chia-Yen Dai.;Jee-Fu Huang.;Nai-Jen Hou.;Li-Po Lee.;Ming-Yen Hsieh.;Chang-Fu Chiu.;Zu-Yau Lin.;Shinn-Cherng Chen.;Ming-Yuh Hsieh.;Liang-Yen Wang.;Wen-Yu Chang.;Wan-Long Chuang.
来源: Gut. 2007年56卷4期553-9页
The recommended treatment for patients infected with hepatitis C virus genotype 2 (HCV2) is pegylated interferon (peginterferon) and ribavirin for 24 weeks.
390. A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results.
作者: P Sharma.;S Wani.;A P Weston.;A Bansal.;M Hall.;S Mathur.;A Prasad.;R E Sampliner.
来源: Gut. 2006年55卷9期1233-9页
Many modalities have been used to ablate Barrett's oesophagus (BO). However, long term results and comparative effectiveness are unknown.
391. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes.
作者: A Mahmood.;A J FitzGerald.;T Marchbank.;E Ntatsaki.;D Murray.;S Ghosh.;R J Playford.
来源: Gut. 2007年56卷2期168-75页
Zinc carnosine (ZnC) is a health food product claimed to possess health-promoting and gastrointestinal supportive activity. Scientific evidence underlying these claims is, however, limited.
392. Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial.
作者: M P Schwartz.;H Wellink.;H G Gooszen.;J M Conchillo.;M Samsom.;A J P M Smout.
来源: Gut. 2007年56卷1期20-8页
Endoscopic treatment for gastro-oesophageal reflux disease (GORD) is rapidly emerging, but there is a great need for randomised controlled trials to evaluate the efficacy.
393. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.
作者: M Sherman.;E M Yoshida.;M Deschenes.;M Krajden.;V G Bain.;K Peltekian.;F Anderson.;K Kaita.;S Simonyi.;R Balshaw.;S S Lee.; .
来源: Gut. 2006年55卷11期1631-8页
The management of patients with chronic hepatitis C who have relapsed or failed to respond to interferon based therapies is an important issue facing hepatologists.
394. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations.
作者: A Federico.;M Trappoliere.;C Tuccillo.;I de Sio.;A Di Leva.;C Del Vecchio Blanco.;C Loguercio.
来源: Gut. 2006年55卷6期901-2页 395. Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy.
Non-cardiac chest pain (NCCP) is an extremely debilitating condition of uncertain origin which is difficult to treat and consequently has a high psychological morbidity. Hypnotherapy has been shown to be effective in related conditions such as irritable bowel syndrome where its beneficial effects are long lasting.
396. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
作者: G Van Assche.;W J Sandborn.;B G Feagan.;B A Salzberg.;D Silvers.;P S Monroe.;W M Pandak.;F H Anderson.;J F Valentine.;G E Wild.;D J Geenen.;R Sprague.;S R Targan.;P Rutgeerts.;V Vexler.;D Young.;R S Shames.
来源: Gut. 2006年55卷11期1568-74页
An uncontrolled pilot study demonstrated that daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), might be effective for the treatment of active ulcerative colitis.
397. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
作者: D W Hommes.;T L Mikhajlova.;S Stoinov.;D Stimac.;B Vucelic.;J Lonovics.;M Zákuciová.;G D'Haens.;G Van Assche.;S Ba.;S Lee.;T Pearce.
来源: Gut. 2006年55卷8期1131-7页
Interferon gamma is a potent proinflammatory cytokine implicated in the inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe CD.
398. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
作者: W Reinisch.;D W Hommes.;G Van Assche.;J-F Colombel.;J-P Gendre.;B Oldenburg.;A Teml.;K Geboes.;H Ding.;L Zhang.;M Tang.;M Cheng.;S J H van Deventer.;P Rutgeerts.;T Pearce.
来源: Gut. 2006年55卷8期1138-44页
This study was designed to evaluate the safety of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease (CD).
399. Perceptual wind-up in the human oesophagus is enhanced by central sensitisation.
Oesophageal acid infusion induces enhanced pain hypersensitivity in non-acid exposed upper oesophagus (secondary hyperalgesia) in patients with non-cardiac chest pain, thus suggesting central sensitisation contributes to visceral pain hypersensitivity in functional gut disorders (FGD). Perceptual wind-up (increased pain perception to constant intensity sensory stimuli at frequencies>or=0.3 Hz) is used as a proxy for central sensitisation to investigate pain syndromes where pain hypersensitivity is important (for example, fibromyalgia).
400. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis.
Immunosuppressive therapy with intravenous ciclosporin is an alternative treatment option to total colectomy for patients with ulcerative colitis (UC), while the benefits of oral administration of tacrolimus are not well defined and are based on reports of several uncontrolled studies.
|